GLP-1RAs: Rethinking treatment intensification in people with T2D - QI&CPD - Category 2


1 hr



# of Credits



QI & CPD - Category 2

Expiry Date


It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.

This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program. Total Points: 2.00 Point(s) (Category 2)

Mark Kennedy
MBBS, BMedSc(Hons), GradDipFamMed
Clinical Associate Professor of General Practice
The University of Melbourne, Melbourne, VIC
Director, Corio Medical Clinical and Coria Diabetic Clinic, Geelong, VIC

Sultan Linjawi
Director, My Health Explained, Brisbane, QLD
Director and Consultant Physician
(Endocrinology and Diabetes)
Coffs Endocrine and Diabetes Services, Coffs Harbor, NSW

On completion of this program, participants will be better able to:

  1. Review current recommendations for treatment intensification for people with type 2 diabetes (T2D) who require treatment intensification beyond oral agents
  2. Assess when injectable therapy should be considered and appreciate the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2D management
  3. Recall the indication, safety and efficacy of GLP-1RAs
  4. Differentiate between GLP-1RA options available in Australia

Related Courses